1. Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease

   • Akira Andoh
   • Atsushi Nishida

   Review 14 November 2022 Pages: 69 - 78

   

2. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum

   • Yoshihiro Kamada
   • Takahiro Nakamura
   • JANIT Forum

   Review Open access 05 December 2022 Pages: 79 - 97

   

3. Supportive treatment during the periprocedural period of endoscopic treatment for pancreatic fluid collections: a critical review of current knowledge and future perspectives

   • Takuji Iwashita
   • Keisuke Iwata
   • Yousuke Nakai

   Review 07 November 2022 Pages: 98 - 111

   

4. Identification of anti-Helicobacter pylori antibody signatures in gastric intestinal metaplasia

   • Lusheng Song
   • Minkyo Song
   • M. Constanza Camargo

   Original Article—Alimentary Tract 27 October 2022 Pages: 112 - 124

   

5. The first comprehensive genomic characterization of rectal squamous cell carcinoma

   • Christoforos Astaras
   • Claudio De Vito
   • Thibaud Koessler

   Original Article—Alimentary Tract Open access 11 November 2022 Pages: 125 - 134

   

6. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan

   • Takashi Ishige
   • Toshiaki Shimizu
   • Tadakazu Hisamatsu

   Original Article—Alimentary Tract Open access 11 January 2023 Pages: 135 - 157

   

7. Impact of mindfulness tendency and physical activity on brain-gut interactions

   • Tomonori Koseki
   • Tomohiko Muratsubaki
   • Shin Fukudo

   Original Article—Alimentary Tract 11 January 2023 Pages: 158 - 170

   

8. Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis

   • Hisashi Nakayama
   • Yukiyasu Okamura
   • Tadatoshi Takayama

   Original Article―liver, Pancreas, and Biliary Tract 02 January 2023 Pages: 171 - 181

   

9. Risk of gastric and oesophageal adenocarcinomas following discontinuation of long-term proton-pump inhibitor therapy

   • Helge Waldum

   Letter to the Editor 17 December 2022 Pages: 182 - 182

10. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy

    • Dag Holmberg
    • Jesper Lagergren

    Letter to the Editor 14 December 2022 Pages: 183 - 183

11. Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry

    • Tomoyuki Satake
    • Chigusa Morizane
    • Akira Kawai

    Correction Open access 23 December 2022 Pages: 184 - 184